Aktienanalyse zu Dare Bioscience Inc (DARE)DAREDare Bioscience Inc

Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dare Bioscience Inc is currently not a good buy due to its significant financial challenges and negative performance trends. The stock is trading at $0.64, which is 83% below its 52-week high of $3.78, indicating substantial downside risk. Additionally, the company has a forward P/E ratio of 1.27, suggesting it may not be valued attractively given its ongoing losses and the need for capital raising as indicated in recent earnings calls.

1 analysts cover DARE: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.